Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do

Abstract

Hepatitis B virus (HBV) infection is a significant health problem that can result in progression to liver cirrhosis, decompensation, and the development of hepatocellular carcinoma (HCC). On a country level, the prevalence of chronic HBV infection varies between 0.1% and 35.0%, depending on the locality and the population being investigated. One-third of all liver cancer fatalities worldwide are attributable to HBV. The adoption of standard birth-dose immunization exerted the most significant impact on the decline of HBV prevalence. HCC incidence ranges from 0.01% to 1.40% in noncirrhotic patients and from 0.9% to 5.4% annually, in the settings of liver cirrhosis. Although antiviral therapy significantly reduces the risk of developing HBV-related HCC, studies have demonstrated that the risk persists, and that HCC screening is still essential. This review discusses the complex relationship between HBV infection and HCC, recent epidemiological data, different aspects of clinical disease characteristics, and the impact of antiviral therapy in this context.

Keywords

Hepatitis B virus (HBV) / Hepatocellular carcinoma (HCC) / HBV vaccine / Carcinogenesis / Antiviral therapy

Authors’ contributions

Mohamed El-Kassas and Walaa Abdelhamed contributed to this manuscript with the conception and design of the work and liter-ature review. Walaa Abdelhamed wrote the first draft of the manuscript. Mohamed El-Kassas provided critical revision and editing. Both authors revised and approved the final version of the manuscript.

Declaration of competing interest

The authors declare that there is no conflicts of interest.

References

[1] Younossi ZM, Yu ML, Yilmaz Y, et al. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Reg-istry. J Viral Hepat. 2023;30:335-344. https://doi.org/10.1111/jvh.13800.

[2] Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002- 2033: the ITA.LI.CA database. Gut. 2023;72:141-152. https://doi.org/10.1136/gutjnl-2021-324915.

[3] Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gas-troenterol Hepatol. 2023;8:879-907. https://doi.org/10.1016/S2468-1253(23)00197-8.

[4] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424. https://doi.org/10.3322/caac.21492.

[5] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun-tries. CA Cancer J Clin. 2021; 71:209-249. https://doi.org/10.3322/caac.21660.

[6] Fernandes da Silva C, Keeshan A, Cooper C. Hepatitis B virus genotypes in-fluence clinical outcomes: a review. Can Liver J. 2023;6:347-352. https://doi.org/10.3138/canlivj-2023-0003.

[7] Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. https://doi.org/10.1101/cshperspect.a021436.

[8] Nasser N, Tonnerre P, Mansouri A, Asselah T. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Curr Opin Virol. 2023;63:101360. https://doi.org/10.1016/j.coviro.2023.101360.

[9] Zhang Y, Yan Q, Gong L, et al. C-terminal truncated HBx initiates hep-atocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene. 2021;40:1147-1161. https://doi.org/10.1038/s41388-020-01593-5.

[10] Wang F, Song H, Xu F, et al. Role of hepatitis B virus non-structural protein HBx on HBV replication, interferon signaling, and hepatocarcinogenesis. Front Microbiol. 2023;14:1322892. https://doi.org/10.3389/fmicb.2023.1322892.

[11] Al Awaidy ST, Ezzikouri S. Moving towards hepatitis B elimination in Gulf Health Council states: from commitment to action. J Infect Public Health. 2020;13:221-227. https://doi.org/10.1016/j.jiph.2019.08.004.

[12] Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int J Epidemiol. 2021;50:560-569. https://doi.org/10.1093/ije/dyaa253.

[13] Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7: 724-735. https://doi.org/10.1016/s2468-1253(22)00050-4.

[14] El-Kassas M, Elbadry M. Hepatocellular carcinoma in Africa: challenges and opportunities. Front Med (Lausanne). 2022;9:899420. https://doi.org/10.3389/fmed.2022.899420.

[15] Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116.

[16] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer sta-tistics. CA Cancer J Clin. 2011;61:69-90. https://doi.org/10.3322/caac.20107.

[17] Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP.Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-125. https://doi.org/10.1093/epirev/mxj009.

[18] Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x.

[19] Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384: 2053-2063. https://doi.org/10.1016/s0140-6736(14)60220-8.

[20] Soriano V, Moreno-Torres V,Treviño A, de Jesús F, Corral O, de Mendoza C. Prospects for controlling hepatitis B globally. Pathogens. 2024;13:291. https://doi.org/10.3390/pathogens13040291.

[21] McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer. 2001;94:290-296. https://doi.org/10.1002/ijc.1456.

[22] Parkin DM, Bray F, Ferlay J, Pisani P.Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108. https://doi.org/10.3322/canjclin.55.2.74.

[23] Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: an update from the national health and nutrition ex-amination survey. J Viral Hepat. 2019;26:596-602. https://doi.org/10.1111/jvh.13060.

[24] Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep. 2023; 72:1-25. https://doi.org/10.15585/mmwr.rr7201a1.

[25] Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-476. https://doi.org/10.1016/s2468-1253(19)30042-1.

[26] Maponga TG, Matteau Matsha R, Morin S, et al. Highlights from the 3rd in-ternational HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. Hepatol Med Policy. 2017;2: 8. https://doi.org/10.1186/s41124-017-0025-0.

[27] Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-583. https://doi.org/10.1016/s0140-6736(11)61097-0.

[28] Venook AP, Papandreou C, Furuse J, The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15:5-13. https://doi.org/10.1634/theoncologist.2010-S4-05.

[29] Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538. https://doi.org/10.1016/j.jhep.2006.05.013.

[30] Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009;49:S56eS60. https://doi.org/10.1002/hep.22962.

[31] Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carci-noma: etiology and management. J Gastrointest Oncol. 2017;8:229-242. https://doi.org/10.21037/jgo.2017.03.14.

[32] Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med. 2009;76:S6eS9. https://doi.org/10.3949/ccjm.76.s3.02.

[33] Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35eS50. https://doi.org/10.1053/j.gastro.2004.09.014.

[34] Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20: 6252-6261. https://doi.org/10.3748/wjg.v20.i20.6252.

[35] Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46: 420-426. https://doi.org/10.1136/gut.46.3.420.

[36] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a bio-logical gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73. https://doi.org/10.1001/jama.295.1.65.

[37] Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140e 1149 (e3). https://doi.org/10.1053/j.gastro.2012.02.007.

[38] Xiao Y, Cao J, Zhang Z, et al. Hepatitis B virus pregenomic RNA reflecting viral replication in distal non-tumor tissues as a determinant of the stemness and recurrence of hepatocellular carcinoma. Front Microbiol. 2022;13:830741. https://doi.org/10.3389/fmicb.2022.830741.

[39] Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53: 1494-1498. https://doi.org/10.1136/gut.2003.033324.

[40] Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenter-ology. 2004;127:1733-1738. https://doi.org/10.1053/j.gastro.2004.09.048.

[41] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73: 1368-1378. https://doi.org/10.1016/j.jhep.2020.07.025.

[42] Xin HG, Xie Q. Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy (in Chinese). Zhonghua Gan Zang Bing Za Zhi. 2021;29:297-300. https://doi.org/10.3760/cma.j.cn501113-20210409-00175.

[43] Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-806. https://doi.org/10.1016/j.jhep.2015.11.035.

[44] Wu S, Zeng N, Sun F, et al. Hepatocellular carcinoma prediction models in chronic hepatitis B: a systematic review of 14 models and external validation. Clin Gastroenterol Hepatol. 2021;19:2499-2513. https://doi.org/10.1016/j.cgh.2021.02.040.

[45] Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP. Pu-rified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci. 1975;270:401-404. https://doi.org/10.1097/00000441-197509000-00025.

[46] Francis DP, Feorino PM, McDougal S, et al. The safety of the hepatitis B vac-cine. Inactivation of the AIDS virus during routine vaccine manufacture. JAMA. 1986;256:869-872.

[47] Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. https://doi.org/10.1038/nrdp.2018.35.

[48] Shouval D. Hepatitis B vaccines. J Hepatol. 2003;39:S70eS76. https://doi.org/10.1016/s0168-8278(03)00152-1.

[49] Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccin Immunother. 2017;13:972-980. https://doi.org/10.1080/21645515.2016.1274473.

[50] Meireles LC, Marinho RT,Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127-2132. https://doi.org/10.4254/wjh.v7.i18.2127.

[51] Kane MA. Global status of hepatitis B immunisation. Lancet. 1996;348:696. https://doi.org/10.1016/s0140-6736(05)65598-5.

[52] Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40:1-25.

[53] Expanded programme on immunization. Global advisory group-Part I. Wkly Epidemiol Rec. 1992;67:11-15.

[54] Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395-403. https://doi.org/10.1016/s1473-3099(02)00315-8.

[55] Implementation of hepatitis B birth dose vaccination e worldwide, 2016. Wkly Epidemiol Rec. 2018;93:61-72.

[56] Pattyn J, Hendrickx G, Vorsters A,Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224:S343eS351. https://doi.org/10.1093/infdis/jiaa668.

[57] Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. Vaccine. 2016;34:2855-2862. https://doi.org/10.1016/j.vaccine.2016.03.060.

[58] Lee BX, Kjaerulf F, Turner S, et al. Transforming our world: implementing the 2030 agenda through sustainable development goal indicators. J Public Health Policy. 2016;37:13-31. https://doi.org/10.1057/s41271-016-0002-7.

[59] Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160274. https://doi.org/10.1098/rstb.2016.0274.

[60] Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9:75. https://doi.org/10.3390/v9040075.

[61] Yang W, Summers J. Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. J Virol. 1998;72:8710-8717. https://doi.org/10.1128/jvi.72.11.8710-8717.1998.

[62] Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479e480:672-686. https://doi.org/10.1016/j.virol.2015.02.031.

[63] Yan H, Yang Y, Zhang L, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology. 2015;61:1821-1831. https://doi.org/10.1002/hep.27722.

[64] Ma J, Sun T, Park S, Shen G, Liu J. The role of hepatitis B virus X protein is related to its differential intracellular localization. Acta Biochim Biophys Sin (Shanghai). 2011;43:583-588. https://doi.org/10.1093/abbs/gmr048.

[65] Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. https://doi.org/10.1016/j.semcancer.2014.01.004.

[66] Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol. 2001;36:651-660. https://doi.org/10.1007/s005350170027.

[67] Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/b-catenin signaling. Cancer Lett. 2011;300:162-172. https://doi.org/10.1016/j.canlet.2010.09.018.

[68] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013.

[69] Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624. https://doi.org/10.1371/journal.pmed.1001624.

[70] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422. https://doi.org/10.1007/s00432-004-0552-0.

[71] Abdelhamed W, El-Kassas M. Hepatocellular carcinoma and hepatitis C virus treatments: the bold and the beautiful. J Viral Hepat. 2023;30:148-159. https://doi.org/10.1111/jvh.13778.

[72] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380. https://doi.org/10.1002/hep.29086.

[73] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69: 182-236. https://doi.org/10.1016/j.jhep.2018.03.019.

[74] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11:317-370. https://doi.org/10.1007/s12072-017-9799-9.

[75] Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015; 45:10.1111/hepr. 12464. https://doi.org/10.1111/hepr.12464.

[76] Salaheldin M, Aly H, Lau L, Afify S, El-Kassas M. Nonalcoholic fatty liver disease-related hepatocellular carcinoma: the next threat after viral hepatitis. Di-agnostics (Basel). 2023;13:2631. https://doi.org/10.3390/diagnostics13162631.

[77] El-Kassas M, Cabezas J, Coz PI, Zheng MH, Arab JP, Awad A. Nonalcoholic fatty liver disease: current global burden. Semin Liver Dis. 2022;42:401-412. https://doi.org/10.1055/a-1862-9088.

[78] Turati F, Galeone C, Rota M, et al. Alcohol and liver cancer: a systematic re-view and meta-analysis of prospective studies. Ann Oncol. 2014;25: 1526-1535. https://doi.org/10.1093/annonc/mdu020.

[79] Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. https://doi.org/10.1016/j.jhep.2015.01.002.

[80] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6: 531-561. https://doi.org/10.1007/s12072-012-9365-4.

[81] Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. https://doi.org/10.1038/s41575-019-0196-9.

[82] Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and un-treated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29:605-622. https://doi.org/10.3350/cmh.2022.0342.

[83] Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. https://doi.org/10.1016/s2468-1253(20)30249-1.

[84] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol-ogy. 2018; 67:1560-1599. https://doi.org/10.1002/hep.29800.

[85] Su TH, Hu TH, Chen CY, et al. Four-year entecavir therapy reduces hepato-cellular carcinoma, cirrhotic events and mortality in chronic hepatitis B pa-tients. Liver Int. 2016;36:1755-1764. https://doi.org/10.1111/liv.13253.

[86] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455. https://doi.org/10.1056/NEJMoa0802878.

[87] Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457-1464. https://doi.org/10.1007/s10620-014-3486-7.

[88] Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631-3638. https://doi.org/10.1002/cncr.29537.

[89] Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral ac-tivity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62:533-540. https://doi.org/10.1016/j.jhep.2014.10.035.

[90] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir dis-oproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196-206. https://doi.org/10.1016/s2468-1253(16)30107-8.

[91] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir dis-oproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185-195. https://doi.org/10.1016/s2468-1253(16)30024-3.

[92] Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158:215e 225 (e6). https://doi.org/10.1053/j.gastro.2019.09.025.

[93] Huang ZH, Lu GY, Qiu LX, et al. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or teno-fovir disoproxil fumarate: a network meta-analysis. BMC Cancer. 2022;22:287. https://doi.org/10.1186/s12885-022-09413-7.

[94] Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis. J Hepatol. 2023;78:534-542. https://doi.org/10.1016/j.jhep.2022.12.007.

[95] Chang TS, Yang YH, Chen WM, et al. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11: 1365. https://doi.org/10.1038/s41598-020-80523-7.

[96] Tsai MC, Wang CC, Lee WC, et al. Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0/A hepatocellular carcinoma after curative resection. Liver Cancer. 2021;11:22-37. https://doi.org/10.1159/000518940.

[97] Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73:661-673. https://doi.org/10.1002/hep.31289.

[98] Yim HJ, Kang SH, Jung YK, et al. Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving long-term besifovir therapy. Cancers (Basel). 2024;16:887. https://doi.org/10.3390/cancers16050887.

[99] Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14:434. https://doi.org/10.3390/v14020434.

[100] Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676-683. https://doi.org/10.1016/j.jhep.2012.11.039.

[101] Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. https://doi.org/10.1007/s12072-019-09989-6.

[102] Hsu YC, Yeh ML, Wong GL, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis. 2021;224:1890-1899. https://doi.org/10.1093/infdis/jiab241.

[103] Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403-410. https://doi.org/10.1016/j.jhep.2009.04.003.